会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Bonding structures for optical members
    • 光学元件的结合结构
    • US06640032B2
    • 2003-10-28
    • US09961786
    • 2001-09-24
    • Jungo KondoTetsuya EjiriTakashi Yoshino
    • Jungo KondoTetsuya EjiriTakashi Yoshino
    • G02B626
    • G02B6/4239G02B6/30G02B6/423G02B6/4234H01L2224/26175H01L2224/45144H01L2924/00
    • An optical member-bonding structure includes a first optical component, a second optical component, and an integral substrate having a mounting face on which the first and second optical components are mounted, at least the first optical member being bonded to the integral substrate, wherein a bonding face of the first optical member is bonded to the mounting face of the integral substrate with a cured and shrunk optical adhesive in such a state that an optical axis of the first optical member is aligned with that of the second optical member at a precision of not more than 1 &mgr;m, a groove is formed in a such bonding region of that mounting face of the integral substrate as being bonded with the first optical member, and at least part of the optical adhesive is filled into the groove.
    • 光学构件接合结构包括第一光学部件,第二光学部件和具有安装有第一和第二光学部件的安装面的一体基板,至少第一光学部件被接合到一体基板,其中, 在第一光学构件的光轴以与第二光学构件的光轴精度对准的状态下,第一光学构件的接合面用固化和收缩的光学粘合剂粘合到整体衬底的安装面 在不超过1um的情况下,在与第一光学构件接合的一体基板的该安装面的接合区域中形成凹槽,并且至少一部分光学粘合剂被填充到凹槽中。
    • 10. 发明授权
    • Imidazo[1,2-C]pyrimidinylacetic acid derivatives
    • 咪唑并[1,2-C]嘧啶基乙酸衍生物
    • US07750014B2
    • 2010-07-06
    • US10585429
    • 2005-01-19
    • Tai-Wei LyTakashi YoshinoYuki TakekawaTakuya ShintaniHiromi SugimotoKevin BaconKlaus Urbahns
    • Tai-Wei LyTakashi YoshinoYuki TakekawaTakuya ShintaniHiromi SugimotoKevin BaconKlaus Urbahns
    • A01N43/90A61K31/519C07D487/00
    • C07D487/04
    • The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
    • 本发明涉及可用作药物制剂活性成分的咪唑并[1,2-c]嘧啶基乙酸衍生物及其盐。 本发明的咪唑并[1,2-c]嘧啶基乙酸衍生物具有优异的CRTH2(G蛋白偶联化学引诱物受体,在Th2细胞上表达)拮抗活性,可用于预防和治疗与CRTH2活性相关的疾病 特别是用于治疗过敏性疾病如哮喘,过敏性鼻炎,特应性皮炎和过敏性结膜炎; 嗜酸性粒细胞相关疾病,如中华综合征和鼻窦炎; 嗜碱性粒细胞相关疾病,如嗜碱性白血病,慢性荨麻疹和人类和其他哺乳动物的嗜碱性白细胞增多症; 以T淋巴细胞为特征的炎性疾病和白血球浸润如银屑病,湿疹,炎性肠病,溃疡性结肠炎,克罗恩病,COPD(慢性阻塞性肺病)和关节炎等。